文献速递中枢神经肿瘤放疗放疗物理与技术

脑转移瘤立体定向放射外科治疗患者配对纵向血液与肿瘤样本的免疫应答

Immunological responses to brain metastasis stereotactic radiosurgery in patient-matched longitudinal blood and tumour samples.
PubMed 文献 · Clin Transl Radiat Oncol · 2024-09-21

该研究分析10例HER2扩增乳腺癌脑转移患者SRS前后7-14天血液样本,并对1例复发后再切除患者的SRS前后肿瘤组织进行多组学分析。结果发现SRS后血液单核细胞、中央记忆CD8+ T和调节性T细胞富集,肿瘤抗原呈递、T细胞增殖与共刺激信号上调,TAM与CD4+ T细胞空间共定位,部分T细胞克隆保留并显著非随机扩增。作者认为SRS可能促进MHC-II限制性T细胞致敏应答。

要点

  • SRS后血液单核细胞、中央记忆CD8+ T及调节性T细胞富集,单核细胞MHC-II表达升高。
  • 肿瘤内抗原呈递、T细胞增殖与共刺激信号上调,TAM与CD4+ T细胞空间共定位。
  • TAM低表达PD-L1而CD4+ T细胞PD-1表达升高,部分T细胞克隆保留并显著非随机扩增。

核心结论

  • 作者认为该同质患者队列的系统与局部免疫变化提示SRS可能促进涉及单核-巨噬细胞系和CD4+ T细胞的MHC-II限制性T细胞致敏应答,需进一步探索。

研究设计与样本

  • 研究分析临床试验中10例HER2扩增乳腺癌脑转移患者SRS前及SRS后7-14天的血液样本,采用质谱流式和流式细胞术检测。
  • 1例患者因脑转移在切除后7个月复发接受术前SRS,SRS后8天按计划再次切除,对SRS前后肿瘤行bulk RNAseq、多重免疫组化和TCR测序。

主要发现

  • 血液中SRS后单核细胞、中央记忆CD8+ T细胞和调节性T细胞富集,单核细胞、常规树突状细胞和单核髓源性抑制细胞MHC-II表达增加。
  • 肿瘤中SRS上调抗原呈递、T细胞增殖和T细胞共刺激特征,并伴肿瘤相关巨噬细胞和CD4+ T细胞浸润。
  • SRS后肿瘤相关巨噬细胞和CD4+ T细胞(而非CD8+ T细胞)显示空间共定位,肿瘤相关巨噬细胞PD-L1低表达而CD4+ T细胞PD-1表达增加。
  • SRS后相当比例T细胞克隆型保留,4个克隆显示显著非随机扩增。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Stereotactic radiosurgery (SRS) is highly effective as focal treatment for brain metastases (BrMs), but whether it can promote anti-tumour immune responses that synergise with immunotherapy remains unclear. We investigated this by examining blood samples from a clinical trial for HER2-amplified breast cancer (HER2-BC) BrMs, matched with longitudinal HER2-BC BrM samples resected from the same location in the same patient. METHODS: Blood samples from 10 patients taken pre- and 7-14 days post-SRS were analysed by mass and flow cytometry. One patient received pre-operative SRS for a BrM that recurred 7 months after resection, followed by planned re-resection 8 days post-SRS. Pre- and post-SRS tumours from this patient were analysed by bulk RNAseq, multiplex immunohistochemistry (mIHC), and TCR sequencing. RESULTS: Monocytes, central memory CD8+ T and regulatory T cells were enriched in blood post-SRS, together with increased MHC-II expression on monocytes, conventional DCs, and monocytic MDSCs. In tumour, SRS upregulated antigen presentation, T cell proliferation and T cell co-stimulation signatures, alongside an influx of tumour-associated macrophages (TAMs) and CD4+ T cells. Specifically, TAMs and CD4+ T cells, but not CD8+ T cells, demonstrated spatial co-localisation post-SRS. These TAMs were lowly PD-L1 expressing, but CD4+ T cells showed increased PD-1 expression. A sizeable proportion of T cell clonotypes were retained post-SRS, and four clones demonstrated significant, non-stochastic expansion. CONCLUSION: Systemic and local immunological changes in this homogenous patient cohort suggest that SRS may facilitate MHC-II-restricted T cell priming responses involving the monocyte-macrophage lineage and CD4+ T cells, which should be further explored.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Sia J, D'Souza C, Castle B, et al. Immunological responses to brain metastasis stereotactic radiosurgery in patient-matched longitudinal blood and tumour samples. Clin Transl Radiat Oncol. 2024. PMID: 39381631. doi:10.1016/j.ctro.2024.100863

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。